Business Standard

India Inc's expenditure on R&D declines to lowest level in six years

Lower expenditure by pharmaceutical companies may be a key reason for the fall

R&D spend went up from 6 per cent of operating income in FY13 to 9 per cent of operating income in FY17. After that there has been a steady decline in the past two financial years
Premium

R&D spend went up from 6 per cent of operating income in FY13 to 9 per cent of operating income in FY17. After that there has been a steady decline in the past two financial years

Sachin P MampattaSohini Das Mumbai
Expenditure on research and development (R&D) by Indian companies has declined to its lowest level in six years.

Of the S&P BSE 500 companies, an analysis of 98 firms (for which continuous data is available over the last decade) shows that their R&D expenditure, on average, came in at 0.54 per cent of net sales.

This is the lowest since 2012-13. The absolute value of R&D expenditure showed a 2.7 per cent fall in FY19, the first decline since at least FY11.

Lower expenditure by pharmaceutical companies may be a key reason for the fall.

ICRA analyst Gaurav Jain said in FY19 major Indian

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in